General MedicationsORALGeneric
Ruxolitinib
Ruxolitinib
Standard Dose
2MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary
Approval overview Ruxolitinib is listed in Drugs@FDA under application 219660 (NDA).
Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient Ruxolitinib Form and strength TABLET; ORAL - 2MG Sponsor APOTEX Submission history Latest submission status date: 2025-11-21 00:00:00.
Structured Monograph
Clinical summary
Approval overview Ruxolitinib is listed in Drugs@FDA under application 219660 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient Ruxolitinib Form and strength TABLET; ORAL - 2MG Sponsor APOTEX Submission history Latest submission status date: 2025-11-21 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: None (Tentative Approval)
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.